Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African Americans04/01/2022 - 03/31/2027 (Multi-PI)
PI:
Naomi Y Ko, MD, MPHThe General Hospital Corporation / MGH NIH NCI1R01CA248923-01A1
Multidimensional Markers of Response and Resistance in advanced breast cancer: CDK4/6 Inhibitors (HR+/HER2-)11/08/2022 - 11/07/2025 (PI)
Bristol-Myers Squibb Company
Multiscale analysis of metabolic inflammation as a driver of breast cancer09/09/2020 - 08/31/2025 (Subcontract PI)
PI:
Naomi Y Ko, MD, MPHTrustees of Boston University, BUMC NIH NCI
Landscape and characterization of promoter mutations driving triple-negative breast cancer07/13/2023 - 06/30/2025 (Subcontract PI)
PI:
Naomi Y Ko, MD, MPHMassachusetts General Hospital NIH1R21CA284602-01
Phase 1b/2 Study to Evaluate Safety and Anti-Tumor Activity of Antibody-Drug Conjugate Sacituzumab Govitecan in Combination with the Poly (Adenosine Diphosphate
[ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Metastatic Triple-Nega06/07/2022 - 12/06/2024 (PI)
Dana Farber Cancer Institute
Mechanisms of BET bromodomain metabolic reprogramming in triple negative breast cancer08/01/2019 - 07/31/2024 (Subcontract PI)
PI:
Naomi Y Ko, MD, MPHTrustees of Boston University, BUMC NIH NCI1R01CA222170-01A1
A wearable probe for deep tissue imaging of hemodynamics in breast tumors01/01/2022 - 06/30/2024 (Subcontract PI)
PI:
Naomi Y Ko, MD, MPHTrustees of Boston University, BUMC Amer Cancer Society
Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer – Core A07/05/2019 - 05/31/2024 (Subcontract PI)
PI:
Naomi Y Ko, MD, MPHDana Farber Cancer Institute NIH NCI2P50CA168504-06A1
Increasing Receipt of Guideline Concordant Survivorship Care Among Black Breast Cancer Survivors…01/01/2020 - 12/31/2023 (Subcontract PI)
PI:
Naomi Y Ko, MD, MPHMassachusetts General Hospital Pfizer, Inc
DFCI 17-101: Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study…01/02/2020 - 01/01/2023 (PI)
Dana Farber Cancer Institute
Showing 10 of 14 results.
Show All Results
Team-based Management of CDK 4/6 inhibitors02/25/2020 - 12/31/2022 (PI)
Pfizer, Inc
Disparities in Breast Cancer Knowledge and Treatment Adherence (ACS Project)01/01/2020 - 12/31/2022 (PI)
Dana Farber Cancer Institute
Improving Cancer Equity: Community-Based Engagement and Interventions01/03/2018 - 02/28/2022 (Subcontract PI)
PI:
Naomi Y Ko, MD, MPHThe General Hospital Corporation / MGH Kraft Ctr Comm Hlth
Disparities in Breast Cancer Knowledge and Treatment Adherence01/01/2020 - 12/31/2020 (Subcontract PI)
PI:
Naomi Y Ko, MD, MPHDana Farber Cancer Institute Amer Cancer Society